AdaptVac has teamed up with ADC Biologics to develop and produce a new coronary pneumonia vaccine

AMC Biologics, a global biopharmaceutical contract development and manufacturing organization, announced that it would work with AdaptVac to develop and produce a new coronary pneumonia vaccine. AdaptVac is working with its co-partners in the development of the SARS-CoV-2 vaccine with its preVENT-nCoV
partner sponsored by the EU Horizon 2020. The new coronary pneumonia pandemic is still spreading, and AdaptVac's virus-like particle (VLP) technology provides solutions to prevent new SARS-CoV-2 infections.AdaptVac's technology could accelerate the development of a new coronary pneumonia vaccine, which is expected to begin clinical trials by the end of 2020. Virus-like particles are a major advance in sub-unit vaccine development, with high safety and efficacy. Particle properties and dense repetitive sub-unit tissue make viral-like particles ideal carriers for displaying vaccine antigens. (U.S. News Agency)